Price chart
Loading 1Y daily…
Financial overlay · last 12 quarters
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-04-30 | $1.1B | $-0.1B | $-0.0B | $0.1B | -7.2% | -2.9% |
| 2026-01-31 | $1.0B | $0.1B | $0.2B | $0.2B | 12.8% | 20.8% |
| 2025-10-31 | $1.1B | $0.1B | $0.1B | $0.1B | 7.9% | 13.2% |
| 2025-07-31 | $1.1B | $0.1B | $0.2B | $0.2B | 9.3% | 16.6% |
| 2025-04-30 | $1.0B | $0.1B | $0.2B | $0.0B | 8.7% | 18.4% |
Earnings replay · last 20 reports
| Date | EPS actual | EPS est | Surprise |
|---|---|---|---|
| 2026-06-04 | 1.21 | 1.09 | +10.5% |
| 2026-03-05 | 1.10 | 1.03 | +7.0% |
| 2025-12-04 | 1.15 | 1.11 | +3.3% |
| 2025-08-27 | 1.10 | 1.07 | +3.0% |
| 2025-05-29 | 0.96 | 0.93 | +3.3% |
| 2025-03-06 | 0.92 | 0.91 | +0.9% |
| 2024-12-05 | 1.04 | 1.00 | +4.0% |
| 2024-08-28 | 0.96 | 0.91 | +5.4% |
| 2024-05-30 | 0.85 | 0.83 | +2.6% |
| 2024-02-29 | 0.85 | 0.78 | +8.5% |
| 2023-12-07 | 0.87 | 0.87 | -0.4% |
| 2023-08-30 | 0.84 | 0.84 | +0.3% |
| 2023-06-01 | 0.77 | 0.76 | +1.7% |
| 2023-03-02 | 0.73 | 0.67 | +7.5% |
| 2022-12-08 | 0.69 | 0.78 | -11.6% |
| 2022-08-31 | 0.80 | 0.81 | -1.2% |
| 2022-06-02 | 0.81 | 0.86 | -5.5% |
| 2022-03-03 | 0.81 | 0.78 | +4.2% |
| 2021-12-02 | 0.82 | 0.84 | -2.9% |
| 2021-09-02 | 0.85 | 0.82 | +3.6% |
Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).
Peer comparison · Healthcare
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| COO ★ | $13B | 57.5 | 13.6 | 3.1 | 17.9 | 1.6 | 65.6% | 7.9% | — | 3.20% |
| LLY | $1,010B | 40.3 | 25.5 | 14.0 | 28.9 | 32.4 | 82.8% | 55.5% | 169.9% | 0.91% |
| UNH | $371B | 30.8 | 19.5 | 0.8 | 19.8 | 3.8 | 18.8% | 2.0% | 0.7% | 4.77% |
| JNJ | $580B | 27.9 | 18.9 | 6.0 | 17.9 | 7.1 | 68.0% | 9.9% | -52.9% | 2.16% |
| MRK | $294B | 33.5 | 12.4 | 4.5 | 11.4 | 6.4 | 76.7% | 4.9% | — | 4.78% |
| ABBV | $402B | 111.1 | 14.0 | 6.4 | 15.6 | -60.5 | 72.0% | 12.4% | -46.2% | 5.17% |
| PFE | $149B | 20.0 | 9.3 | 2.4 | 7.9 | 1.7 | 74.8% | 5.4% | -10.1% | 8.29% |
| TMO | $174B | 25.8 | 17.2 | 3.9 | 19.0 | 3.3 | 40.9% | 6.2% | 11.3% | 3.17% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Top institutional holders
Top-10 concentration: 44.92%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 16,618,129 | 8.52% |
| Vanguard Capital Management LLC | 12,718,829 | 6.52% |
| T. Rowe Price Investment Management, | 9,060,177 | 4.65% |
| State Street Corporation | 8,768,419 | 4.50% |
| Vanguard Portfolio Management LLC | 8,721,331 | 4.47% |
| Capital World Investors | 7,414,949 | 3.80% |
| Browning West Lp | 6,979,529 | 3.58% |
| Kayne Anderson Rudnick Investment Ma | 6,616,677 | 3.39% |
| Price (T.Rowe) Associates Inc | 5,393,880 | 2.77% |
| Geode Capital Management, LLC | 5,311,523 | 2.72% |
Insider activity · 90d
0 buys / 0 sells · ratio 0.0 · Finnhub
- Rosebrough Walter M Jr 0
- Rosebrough Walter M Jr 832
- Carbone Barbara 3,779
- Carbone Barbara 0
- Carbone Barbara 3,050
- Rivas Maria 3,779
- Rivas Maria 0
- Rivas Maria 3,322
- Jay Colleen 4,157
- Jay Colleen 0
Analyst estimates
FinnhubSEC filings
| Form | Filed | Description | Action |
|---|---|---|---|
| 10-Q | 2026-06-05 | 10-Q | view · |
| 8-K | 2026-06-04 | 8-K | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 4 | 2026-04-21 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-04-08 | 8-K | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-04-06 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-03-06 | 10-Q | view · |
| 8-K | 2026-03-05 | 8-K | view · |
| DEF 14A | 2026-02-24 | DEF 14A | view · |
| 8-K | 2026-02-04 | 8-K | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-12 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-12 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-12 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-12 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-12 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-12-23 | 8-K | view · |
| 4 | 2025-12-23 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-19 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-17 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-15 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-12-12 | 8-K | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 10-K | 2025-12-05 | 10-K | view · |
| 8-K | 2025-12-04 | 8-K | view · |
| 4 | 2025-09-29 | PRIMARY DOCUMENT | view · |
| 4 | 2025-09-05 | PRIMARY DOCUMENT | view · |
| 4 | 2025-09-05 | PRIMARY DOCUMENT | view · |
| 4 | 2025-09-02 | PRIMARY DOCUMENT | view · |
| 4 | 2025-09-02 | PRIMARY DOCUMENT | view · |
| 10-Q | 2025-08-28 | 10-Q | view · |
| 8-K | 2025-08-27 | 8-K | view · |
| 10-Q | 2025-05-30 | 10-Q | view · |
| 8-K | 2025-05-29 | 8-K | view · |
| 4 | 2025-05-05 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-04-30 | 8-K | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-04-03 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-04-02 | 8-K | view · |
| 10-Q | 2025-03-07 | 10-Q | view · |
| 8-K | 2025-03-06 | 8-K | view · |
About
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.